Show simple item record

dc.contributor.authorSimon, C
dc.contributor.authorGerken, G
dc.contributor.authorHansen, B
dc.contributor.authorZondervan, P
dc.contributor.authorNiesters, HGM
dc.contributor.authorde Man, RA
dc.contributor.authorSo, TMJ
dc.contributor.authorSchalm, SW
dc.contributor.authorJanssen, HLA
dc.contributor.authorvan Zonneveld, M
dc.contributor.authorSenturk, H
dc.contributor.authorZeuzem, S
dc.contributor.authorAkarca, US
dc.contributor.authorCakaloglu, Y
dc.date.accessioned2021-03-06T11:26:15Z
dc.date.available2021-03-06T11:26:15Z
dc.date.issued2005
dc.identifier.citationJanssen H., van Zonneveld M., Senturk H., Zeuzem S., Akarca U., Cakaloglu Y., Simon C., So T., Gerken G., de Man R., et al., "Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised", LANCET, cilt.365, ss.123-129, 2005
dc.identifier.issn0140-6736
dc.identifier.othervv_1032021
dc.identifier.otherav_ef01511b-0334-4453-bc8b-57c249083e6b
dc.identifier.urihttp://hdl.handle.net/20.500.12627/156883
dc.identifier.urihttps://doi.org/10.1016/s0140-6736(05)17701-0
dc.description.abstractBackground Treatment of HBeAg-positive patients with chronic hepatitis B is not effective in most. A combination of immunomodulatory pegylated interferon alfa-2b and antiviral lamivudine might improve the rate of sustained response.
dc.language.isoeng
dc.subjectTemel Tıp Bilimleri
dc.subjectTIP, GENEL & İÇECEK
dc.subjectKlinik Tıp
dc.subjectKlinik Tıp (MED)
dc.subjectTıp
dc.subjectSağlık Bilimleri
dc.titlePegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised
dc.typeMakale
dc.relation.journalLANCET
dc.contributor.department, ,
dc.identifier.volume365
dc.identifier.issue9454
dc.identifier.startpage123
dc.identifier.endpage129
dc.contributor.firstauthorID174222


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record